Top pick for banking + investing in one app
- Trade stocks, options, ETFs and mutual funds
- Access to a financial planner
- All-in-one app for banking and investing
- Automated investing available
Top pick for banking + investing in one app
Get 12 free shares
Top pick for bank-integrated investing
Lixte Biotechnology Holdings is an electrical equipment & parts business based in the US. Lixte Biotechnology Holdings shares (LIXT) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $3.66 – the same closing value as a week prior. Lixte Biotechnology Holdings employs 3 staff and has a market cap (total outstanding shares value) of $125.4 million.
Looking for other options? Check out these similar products.
How we picked theseThe Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on eight different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.66 |
|---|---|
| 52-week range | $2.36 - $8.38 |
| 50-day moving average | $6.11 |
| 200-day moving average | $4.34 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.14 |
Historical closes compared with the close of $3.66 from 2026-09-03
| 1 week (2026-10-28) | N/A |
|---|---|
| 1 month (2026-10-04) | N/A |
| 3 months (2026-08-07) | 1.67% |
| 6 months (2026-05-08) | -29.07% |
| 1 year (2025-11-07) | -13.88% |
|---|---|
| 2 years (2024-11-08) | 116.57% |
| 3 years (2023-11-08) | 30.71% |
| 5 years (2021-11-08) | -82.23% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -64.5% |
| Return on equity TTM | -140.99% |
| Profit margin | 0% |
| Book value | $0.68 |
| Market Capitalization | $125.4 million |
TTM: trailing 12 months
We're not expecting Lixte Biotechnology Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
Lixte Biotechnology Holdings's shares were split on a 1:10 basis on 4 June 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology Holdings shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Lixte Biotechnology Holdings shares which in turn could have impacted Lixte Biotechnology Holdings's share price.
Over the last 12 months, Lixte Biotechnology Holdings's shares have ranged in value from as little as $2.36 up to $8.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Lixte Biotechnology Holdings's is 1.251. This would suggest that Lixte Biotechnology Holdings's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Lixte Biotechnology Holdings's beta into context you can compare it against those of similar companies.
Seven brokers open IPO share requests to retail investors — but minimums, odds and flipping rules vary sharply.
Our top 10 beginner-friendly stocks and ETFs, and why we picked them — plus 7 more.
Discover the best robo-advisors of 2026. Compare fees, account minimums and features from top platforms that automate investing for beginners and pros.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
We’ve rounded up stats on some of the most popular oil stocks, along with information on how they compare and how to invest.
Six stocks that cleared our November 2026 screen for quality, growth and balance-sheet strength.
What to consider before you invest in biotechnology companies.
Copper is an industrial metal with many applications. Here’s what you should consider before investing.
Top stocks and ETFs to consider for those ready to invest in cannabis.
Here’s what a blue chip stock is, including examples, as well as what makes it attractive to investors and how to buy and sell them.
Finder is a comparison platform and information service designed to help you make better decisions. To keep our service free, we receive compensation from the companies whose products or services we feature on our site.
We may be paid when you click on a link, submit an application, or open an account.
Our commercial arrangements affect which products we write about, as well as the inclusion, order, position and placement of products on our site. They do not influence our independent assessments or editorial views, which are based on research and expert analysis conducted by our editorial team.
The inclusion of a provider or product in our content, or the order in which products appear in tables or lists, is not an endorsement or recommendation from us.
We compare a wide range of products, providers and services, but we don't cover the whole market. Not every company or offer available is included on our site, and other options may be available to you.
The information we provide is general in nature and is not financial, investment, tax or legal advice. Consider your own circumstances and read the provider's terms and conditions before making a decision.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.